Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments